IDXX

IDEXX Laboratories, Inc. [IDXX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

IDXX Stock Summary

Top 10 Correlated ETFs

IDXX


Top 10 Correlated Stocks

IDXX


In the News

02:00 22 Feb 2024 IDXX

IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 29, 10:50 am – 11:30 am EST – Brian McKeon, Executive Vice President and Chief Financial Officer, and Tina Hunt, PhD, Executive Vice President, Strategy, Sector Development and Global Operations, will participate in a fireside chat at the BofA Securities Animal Health Virtual Summit. Monday, March 4, 11:00 am –.

02:01 22 Feb 2024 IDXX

IDEXX (IDXX) Unveils Pet Owner Engagement Software Solution

IDEXX's (IDXX) Vello software is an intuitive solution designed specifically for practice management software that enables practitioners to interact with pet owners before and after visits.

12:56 22 Feb 2024 IDXX

Here's Why You Should Retain IDEXX (IDXX) Stock for Now

IDEXX Laboratories, Inc. IDXX is likely to grow in the coming quarters, backed by the sustained success of CAG's recurring diagnostic products and services. The company's international business performance is gaining from its expanded global commercial capability.

11:35 22 Feb 2024 IDXX

IDEXX's (IDXX) Global Growth Continues, Currency Woes Persist

A key element of IDEXX's (IDXX) customer engagement strategy is the expansion of its commercial footprint in a disciplined approach.

12:02 22 Feb 2024 IDXX

IDEXX Laboratories, Inc. (IDXX) Q4 2023 Earnings Call Transcript

IDEXX Laboratories, Inc. (IDXX) Q4 2023 Earnings Call Transcript

11:41 22 Feb 2024 IDXX

IDEXX (IDXX) Q4 Earnings Surpass Estimates, Margins Fall

Across testing modalities, IDEXX (IDXX) achieves strong global growth in the fourth quarter.

10:31 22 Feb 2024 IDXX

Idexx (IDXX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Idexx (IDXX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

08:41 22 Feb 2024 IDXX

Idexx Laboratories (IDXX) Q4 Earnings and Revenues Top Estimates

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.32 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $2.05 per share a year ago.

09:51 22 Feb 2024 IDXX

Should You Buy IDEXX Laboratories (IDXX) Ahead of Earnings?

IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

12:40 22 Feb 2024 IDXX

IQV or IDXX: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Idexx Laboratories (IDXX). But which of these two companies is the best option for those looking for undervalued stocks?

IDXX Financial details

Company Rating
Strong Buy
Market Cap
46.14B
Income
-
Revenue
-
Book val./share
17.87
Cash/share
5.46
Dividend
-
Dividend %
-
Employees
11K
Optionable
No
Shortable
Yes
Earnings
30 Apr 2024
P/E
55.86
Forward P/E
-
PEG
-
P/S
12.8
P/B
35.42
P/C
104.82
P/FCF
66.59
Quick Ratio
0.81
Current Ratio
1.43
Debt / Equity
0.47
LT Debt / Equity
0.42
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
1.58
EPS this Y
25.28%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
15.4%
Revenue last 5Y
8.75%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
6.87%
SMA50
8.53%
SMA100
27.85%
Inst Own
72.57%
Inst Trans
0.84%
ROA
27%
ROE
86%
ROC
0.51%
Gross Margin
60%
Oper. Margin
30%
Profit Margin
23%
Payout
-
Shs Outstand
83.05M
Shs Float
82.2M
-
-
-
-
Target Price
478.5
52W Range
372.5-579.68
52W High
-1.16%
52W Low
+53.85%
RSI
55
Rel Volume
0.34
Avg Volume
483.3K
Volume
164.78K
Perf Week
3%
Perf Month
3.26%
Perf Quarter
11.91%
Perf Half Y
18.74%
-
-
-
-
Beta
1.253
-
-
Volatility
7.38%, 20.59%
Prev Close
3.16%
Price
572.31
Change
3.68%

IDXX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
27.9531.7237.7440.2744.07
Net income per share
4.976.828.748.1210.17
Operating cash flow per share
5.337.598.876.4910.91
Free cash flow per share
3.536.337.464.719.3
Cash per share
1.054.51.71.350
Book value per share
2.067.418.17.280
Tangible book value per share
-1.43.952.721.790
Share holders equity per share
2.067.418.17.280
Interest debt per share
11.8211.0311.1916.590
Market cap
22.49B42.66B56.1B34.11B46.11B
Enterprise value
23.38B43.18B56.88B35.35B0
P/E ratio
52.5773.3375.3250.2454.56
Price to sales ratio
9.3415.7617.4510.1312.59
POCF ratio
48.9765.8374.2562.8350.86
PFCF ratio
73.9978.9488.2186.5559.65
P/B Ratio
126.7167.4981.3156.040
PTB ratio
126.7167.4981.3156.040
EV to sales
9.7215.9517.6910.50
Enterprise value over EBITDA
42.362.1861.0339.330
EV to operating cash flow
50.9366.6475.2865.10
EV to free cash flow
76.9479.9189.4389.690
Earnings yield
0.020.010.010.020.02
Free cash flow yield
0.010.010.010.010.02
Debt to equity
5.571.441.342.220
Debt to assets
0.540.40.380.490
Net debt to EBITDA
1.620.760.841.380
Current ratio
0.941.821.250.890
Interest coverage
18.0521.3431.7323.17-30.52
Income quality
1.071.111.010.81.07
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.110.110.10.10.09
Research and developement to revenue
0.060.050.050.080.05
Intangibles to total assets
0.160.130.190.170
Capex to operating cash flow
-0.34-0.17-0.16-0.27-0.15
Capex to revenue
-0.06-0.04-0.04-0.04-0.04
Capex to depreciation
-1.76-1.12-1.14-1.330
Stock based compensation to revenue
0.020.010.010.010
Graham number
15.1833.7139.9136.470
ROIC
0.360.370.450.340
Return on tangible assets
0.280.290.380.30
Graham Net
-14.69-10.83-13.99-18.430
Working capital
-45.7M479.98M192.08M-134.33M0
Tangible asset value
-120.37M336.91M231.61M149.27M0
Net current asset value
-975.01M-599.03M-791.56M-1.04B0
Invested capital
5.571.441.342.220
Average receivables
259.08M300.37M349.89M384.48M0
Average payables
70.85M73.37M95.35M113.18M0
Average inventory
184.16M202.45M239.45M318.43M0
Days sales outstanding
40.8444.6941.8143.420
Days payables outstanding
25.323.9631.9729.520
Days of inventory on hand
68.3567.4674.0698.50
Receivables turnover
8.948.178.738.410
Payables turnover
14.4315.2311.4212.370
Inventory turnover
5.345.414.933.710
ROE
2.410.921.081.120
Capex per share
-1.8-1.26-1.4-1.78-1.61

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
9.9910.8511.3611.0210.85
Net income per share
2.082.582.72.552.34
Operating cash flow per share
2.092.222.413.280
Free cash flow per share
1.621.742.082.870
Cash per share
1.361.341.63.995.46
Book value per share
7.3410.1313.1715.6117.87
Tangible book value per share
1.84.627.6910.2117.87
Share holders equity per share
7.3410.1313.1715.6117.87
Interest debt per share
16.4214.6512.5912.178.33
Market cap
33.83B41.5B41.73B36.34B46.12B
Enterprise value
35.07B42.59B42.63B37.02B46.36B
P/E ratio
49.1248.4746.5242.859.27
Price to sales ratio
40.8346.144.2239.6951.15
POCF ratio
195.09225.67208.31133.380
PFCF ratio
252.12287.41241.42152.450
P/B Ratio
55.5849.3438.1528.0131.07
PTB ratio
55.5849.3438.1528.0131.07
EV to sales
42.3347.3245.1840.4451.42
Enterprise value over EBITDA
154.81151.91143.95134.49189
EV to operating cash flow
202.21231.6212.82135.90
EV to free cash flow
261.33294.97246.65155.340
Earnings yield
0.010.010.010.010
Free cash flow yield
0000.010
Debt to equity
2.221.430.950.790.47
Debt to assets
0.490.430.360.330.21
Net debt to EBITDA
5.463.893.052.50.99
Current ratio
0.891.081.331.431.57
Interest coverage
17.0222.0628.99-37.24-43.54
Income quality
1.010.860.891.280
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.10.080.10.10.1
Research and developement to revenue
0.050.050.050.050.06
Intangibles to total assets
0.170.160.160.150
Capex to operating cash flow
-0.23-0.21-0.14-0.130
Capex to revenue
-0.05-0.04-0.03-0.040
Capex to depreciation
-1.37-1.39-0.9900
Stock based compensation to revenue
0.020.020.0200
Graham number
18.5224.2528.2729.9530.68
ROIC
0.090.10.10.090.09
Return on tangible assets
0.080.090.090.080.06
Graham Net
-18.58-15.98-13.24-11.08-9.49
Working capital
-134.33M83.82M295.17M414.04M543.71M
Tangible asset value
149.27M383.8M638.72M848.51M1.48B
Net current asset value
-1.04B-817.85M-597.92M-404.77M-280.14M
Invested capital
2.221.430.950.790.47
Average receivables
437.92M423.32M453.94M457.28M455.07M
Average payables
110.18M113.97M112.69M110.14M111.63M
Average inventory
361.4M379.42M393.08M394.56M387.13M
Days sales outstanding
43.5244.5944.0544.545.66
Days payables outstanding
28.8729.6626.1327.5726.52
Days of inventory on hand
96.3398.5195.9196.4791.16
Receivables turnover
2.072.022.042.021.97
Payables turnover
3.123.033.443.263.39
Inventory turnover
0.930.910.940.930.99
ROE
0.280.250.20.160.13
Capex per share
-0.47-0.48-0.33-0.410

IDXX Frequently Asked Questions

What is IDEXX Laboratories, Inc. stock symbol ?

IDEXX Laboratories, Inc. is a US stock , located in Westbrook of Me and trading under the symbol IDXX

Is IDEXX Laboratories, Inc. buy or a sell ?

10 stock analysts have 10 predictions with a medium analyst target price of $480.1. The lowest prediction is $247 and the highest is $700

What is IDXX stock prediction ?

What is IDEXX Laboratories, Inc. stock quote today ?

IDEXX Laboratories, Inc. stock price is $572.31 today.

Is IDEXX Laboratories, Inc. stock public?

Yes, IDEXX Laboratories, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap